Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, 130 Mason Farm Road, Chapel Hill, NC 27599-7080, USA.
Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Alabama at Birmingham/Children's of Alabama, 1600 7th Avenue South, Birmingham, AL 35233-1785, USA.
Immunol Allergy Clin North Am. 2024 May;44(2):397-406. doi: 10.1016/j.iac.2024.01.010. Epub 2024 Feb 10.
Data for pharmacologic treatments for non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal diseases (EGIDs) are limited. Nevertheless, because of the increasing understanding of EGID pathogenesis, a number of medications are used to treat EGIDs, though all are currently off-label. Initial therapy generally starts with corticosteroids, and "topical" delivery is preferred over systemic due to long-term side effects. A number of other small molecules could potentially be used, ranging from allergy medications to immunosuppressants. Biologics are also being used and investigated for EGIDs and represent promising targeted therapies. Multiple therapeutic targets have also been identified, many of which overlap with EoE targets.
用于非嗜酸性食管炎(EoE)嗜酸性胃肠病(EGIDs)的药物治疗数据有限。尽管如此,由于对 EGID 发病机制的认识不断加深,许多药物被用于治疗 EGIDs,尽管这些药物目前都没有被批准用于该适应证。初始治疗通常从皮质类固醇开始,由于长期副作用,“局部”给药优于全身给药。还有许多其他小分子药物也可能被用于治疗 EGIDs,范围从过敏药物到免疫抑制剂。生物制剂也被用于治疗 EGIDs 并正在进行研究,代表了有前途的靶向治疗方法。也已经确定了多个治疗靶点,其中许多与 EoE 靶点重叠。